2-Hydrazinopyridine → 2-methyl-N-[3-[1-[(4E)-4-phenyl-4-(pyridin-2-ylhydrazinylidene)butyl]piperidin-4-yl]phenyl]propanamide
반응식
C1(N2C3C(=CC=CC=3)C(CCCN3CCC(C4C=C(NC(=O)C(C)C)C=CC=4)CC3)=C2C2C=CC=CC=2)C=CC=CC=1.[CH3:43][CH:44]([CH3:71])[C:45]([NH:47][C:48]1[CH:53]=[CH:52][CH:51]=[C:50]([CH:54]2[CH2:59][CH2:58][N:57]([CH2:60][CH2:61][CH2:62][C:63](=O)[C:64]3[CH:69]=[CH:68][CH:67]=[CH:66][CH:65]=3)[CH2:56][CH2:55]2)[CH:49]=1)=[O:46].[NH:72]([C:74]1[CH:79]=[CH:78][CH:77]=[CH:76][N:75]=1)[NH2:73]>>[CH3:43][CH:44]([CH3:71])[C:45]([NH:47][C:48]1[CH:53]=[CH:52][CH:51]=[C:50]([CH:54]2[CH2:59][CH2:58][N:57]([CH2:60][CH2:61][CH2:62]/[C:63](/[C:64]3[CH:69]=[CH:68][CH:67]=[CH:66][CH:65]=3)=[N:73]\[NH:72][C:74]3[CH:79]=[CH:78][CH:77]=[CH:76][N:75]=3)[CH2:56][CH2:55]2)[CH:49]=1)=[O:46]참가 물질
4
반응물 3
생성물 1
실험 절차
According to the procedure used for the synthesis of N-(3-{1-[3-(1,2-diphenyl-1H-indol-3-yl)propyl]-4-piperidinyl}phenyl)-2-methylpropanamide, 2-methyl-N-{3-[1-(4-oxo-4-phenylbutyl)-4-piperidinyl]phenyl}propanamide (8.70 mg, 0.0223 mmol) and 2-hydrazinopyridine (2.92 mg, 0.0268 mmol) provided 2-methyl-N-(3-{1-[(4E)-4-phenyl-4-(2-pyridinylhydrazono)butyl]-4-piperidinyl}phenyl)propanamide (2.5 mg, 24%). 1H NMR (400 MHz, CDCl3) δ 7.97 (d, 1H, J=8.6 Hz), 7.85 (d, 1H, J=7.3 Hz), 7.64–7.27 (m, 9H), 7.09 (d, 1H, J=8.0 Hz), 6.97 (d, 1H, J=8.4 Hz), 6.73 (q, 1H, J=6.6 Hz), 3.52–3.48 (m, 2H), 3.20–3.10 (m, 2H), 2.85–1.75 (m, 13H), 1.26 (d, 6H, J=6.8 Hz); ESMS m/e: 484.4 (M+H)+.
출처 및 근거
- ORD 기록
- ord-dad6bfc6a2194f148e16b4d80e3934df
- 출처 데이터셋
- uspto-grants-2006_06
- 특허 번호
- US07067534B1
반응 노트
불러오는 중…